Cargando…
Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle acti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704199/ https://www.ncbi.nlm.nih.gov/pubmed/33299611 http://dx.doi.org/10.1155/2020/8816824 |
_version_ | 1783616773289934848 |
---|---|
author | Segar, Jennifer M. Pandey, Ritu Farr, Kiah J. Nagle, Raymond LeBeau, Lauren Gonzalez, Victor J. Chalasani, Pavani |
author_facet | Segar, Jennifer M. Pandey, Ritu Farr, Kiah J. Nagle, Raymond LeBeau, Lauren Gonzalez, Victor J. Chalasani, Pavani |
author_sort | Segar, Jennifer M. |
collection | PubMed |
description | Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle activation. We identified PILC and ILC tumors and tested for PI3K/Akt/mTOR pathway activation by immunohistochemistry (PTEN and pS6K1) and gene expression analysis (by Nanostring nCounter system). Proliferation index (Ki67) was elevated in 85% of PILCs compared to 20% of ILCs (p < 0.007). PTEN expression was high in all while pS6K1 was high in 8/9 PILCs compared to 3/9 ILCs (p < 0.007). Gene expression analysis shows that PILCs have overexpression of genes involved in cell cycle proliferation, cellular proliferation, DNA damage, and repair genes but no difference in PI3K/Akt/mTOR pathway genes. PILCs are a biologically distinct group of ILC, and clinicopathological characteristics suggest they would have a more clinically aggressive behavior. In addition, our results indicate that PI3k/Akt/mTOR pathway and cell cycle proliferation are activated in majority of these tumors. Further studies are needed to investigate these mechanisms as there are approved therapies available that may benefit PILCs. |
format | Online Article Text |
id | pubmed-7704199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-77041992020-12-08 Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma Segar, Jennifer M. Pandey, Ritu Farr, Kiah J. Nagle, Raymond LeBeau, Lauren Gonzalez, Victor J. Chalasani, Pavani Int J Breast Cancer Research Article Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle activation. We identified PILC and ILC tumors and tested for PI3K/Akt/mTOR pathway activation by immunohistochemistry (PTEN and pS6K1) and gene expression analysis (by Nanostring nCounter system). Proliferation index (Ki67) was elevated in 85% of PILCs compared to 20% of ILCs (p < 0.007). PTEN expression was high in all while pS6K1 was high in 8/9 PILCs compared to 3/9 ILCs (p < 0.007). Gene expression analysis shows that PILCs have overexpression of genes involved in cell cycle proliferation, cellular proliferation, DNA damage, and repair genes but no difference in PI3K/Akt/mTOR pathway genes. PILCs are a biologically distinct group of ILC, and clinicopathological characteristics suggest they would have a more clinically aggressive behavior. In addition, our results indicate that PI3k/Akt/mTOR pathway and cell cycle proliferation are activated in majority of these tumors. Further studies are needed to investigate these mechanisms as there are approved therapies available that may benefit PILCs. Hindawi 2020-11-22 /pmc/articles/PMC7704199/ /pubmed/33299611 http://dx.doi.org/10.1155/2020/8816824 Text en Copyright © 2020 Jennifer M. Segar et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Segar, Jennifer M. Pandey, Ritu Farr, Kiah J. Nagle, Raymond LeBeau, Lauren Gonzalez, Victor J. Chalasani, Pavani Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma |
title | Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma |
title_full | Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma |
title_fullStr | Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma |
title_full_unstemmed | Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma |
title_short | Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma |
title_sort | clinicopathological and molecular characteristics of pleomorphic invasive lobular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704199/ https://www.ncbi.nlm.nih.gov/pubmed/33299611 http://dx.doi.org/10.1155/2020/8816824 |
work_keys_str_mv | AT segarjenniferm clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma AT pandeyritu clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma AT farrkiahj clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma AT nagleraymond clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma AT lebeaulauren clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma AT gonzalezvictorj clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma AT chalasanipavani clinicopathologicalandmolecularcharacteristicsofpleomorphicinvasivelobularcarcinoma |